Literature DB >> 8342278

Overcoming the limitations of chemotherapy in the treatment of B-cell non-Hodgkin's lymphomas--an approach using radiolabeled peptide ligands.

M F Renschler, R Levy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8342278      PMCID： PMC1022146     

Source DB:  PubMed          Journal:  West J Med        ISSN： 0093-0415


× No keyword cloud information.
  8 in total

1.  Selective enrichment and characterization of high affinity ligands from collections of random peptides on filamentous phage.

Authors:  R W Barrett; S E Cwirla; M S Ackerman; A M Olson; E A Peters; W J Dower
Journal:  Anal Biochem       Date:  1992-08-01       Impact factor: 3.365

2.  Twenty years of MOPP therapy for Hodgkin's disease.

Authors:  D L Longo; R C Young; M Wesley; S M Hubbard; P L Duffey; E S Jaffe; V T DeVita
Journal:  J Clin Oncol       Date:  1986-09       Impact factor: 44.544

Review 3.  Treatment of B-cell lymphoma using peptides. A novel concept.

Authors:  K S Lam
Journal:  West J Med       Date:  1993-05

4.  Peptides on phage: a vast library of peptides for identifying ligands.

Authors:  S E Cwirla; E A Peters; R W Barrett; W J Dower
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

5.  MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma.

Authors:  P Klimo; J M Connors
Journal:  Ann Intern Med       Date:  1985-05       Impact factor: 25.391

6.  Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.

Authors:  D L Longo; V T DeVita; P L Duffey; M N Wesley; D C Ihde; S M Hubbard; M Gilliom; E S Jaffe; J Cossman; R I Fisher
Journal:  J Clin Oncol       Date:  1991-01       Impact factor: 44.544

7.  Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma.

Authors:  E M McKelvey; J A Gottlieb; H E Wilson; A Haut; R W Talley; R Stephens; M Lane; J F Gamble; S E Jones; P N Grozea; J Gutterman; C Coltman; T E Moon
Journal:  Cancer       Date:  1976-10       Impact factor: 6.860

8.  Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD).

Authors:  A T Skarin; G P Canellos; D S Rosenthal; D C Case; J M MacIntyre; G S Pinkus; W C Moloney; E Frei
Journal:  J Clin Oncol       Date:  1983-02       Impact factor: 44.544
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.